GAO Considers FDA Data Insufficient To Predict FY 2005 Review Performance
This article was originally published in The Gray Sheet
The high volume of fiscal 2003 and 2004 submissions still pending at FDA precludes a thorough assessment of whether the agency will be able to meet FY 2005 device review performance goals under MDUFMA, according to the Government Accountability Office
You may also be interested in...
Second read-out maintains 94% level of efficacy, with a very early signal that it could outperform Pfizer’s rival mRNA candidate in preventing severe cases.
The French major and Regeneron have racked up another indication for Dupixent with the blockbuster getting approval in Europe to treat children with severe eczema.
Russia says it will make the first deliveries of its $10-per-dose Sputnik V vaccine in January, while international regulators say vaccine trials should continue for as long as possible to generate longer-term evidence on their benefits and risks. A UK research body has stressed that drugs repurposed for COVID-19 also need to undergo thorough safety and efficacy testing as reports suggest the UK regulator could approve a vaccine within days.